RecruitMe Clinical Trial

An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination with Eribulin versus Eribulin alone in Patients with HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Study of HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (FORTRESS)
Sponsor:Polyphor
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS7020
U.S. Government ID:NCT03786094
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this research study is to determine if the experimental drug balixafortide combined with eribulin is well tolerated and more effective for treating breast cancer compared with eribulin given alone. Balixafortide (POL6326) interacts with proteins called CXCR4 receptors which may directly suppress tumor growth through disruption of signaling pathways. Eribulin is FDA approved for the treatment of metastatic breast cancer.

Do You Qualify?
Are you 18 years old, or older?YesNo
Do you have confirmed diagnosis of breast cancer that is metastatic or unresectable (cannot be removed through surgery)?YesNo
Is your breast cancer type HER2 negative?YesNo
Have you received between 1-4 chemotherapy regimens?YesNo
Submit
Cancel
Investigator
Melissa Accordino, MD, MS
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162